Pain, Fatigue and Life Quality in COVID-19 Patients
Assessment of Pain, Fatigue and Quality of Life in COVID-19 Patients
調査の概要
詳細な説明
Patients over the age of 18 who are hospitalized in the Pandemic Service, and are positive for COVID-19 PCR, will be included in the study if the participants read the informed consent form and volunteer for the study.
Patients' age, comorbidities, initial symptoms, and pneumonia severity (mild/moderate/severe) will be recorded. Pain, fatigue and depression assessments will be made on the first day of hospitalization, at discharge, at the 1st month and 3rd month after discharge. The 1st and 3rd month evaluations of the patients will be made by contacting the participants by phone. In addition to the 1st and 3rd month evaluations, the quality of life will also be evaluated with the SF-12 questionnaire.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Ali İzzet MD AKÇİN
- 電話番号:+905469347374
- メール:dr.akcin93@gmail.com
研究場所
-
-
-
Afyonkarahi̇sar、七面鳥、03200
- 募集
- Afyonkarahisar Health Sciences University
-
コンタクト:
- Ali İzzet MD AKÇİN
- 電話番号:+905469347374
- メール:dr.akcin93@gmail.com
-
コンタクト:
- Sevda MD ADAR
- 電話番号:+905325940725
- メール:drsevdaadar@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria: Patients over the age of 18 who are hospitalized in the Pandemic Service, and are positive for COVID-19 PCR, will be included in our study.
- Patient with Covid 19 Pneumonia
Exclusion Criteria:
- Uncooperative Patient,
- Illiterate Patients,
- Pregnancy,
- Patients with Chronic Pain or Fatigue in the last 6 months (before COVID-19 disease),
- Patients who were admitted to the intensive care unit during their hospitalization
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:ケースコントロール
- 時間の展望:見込みのある
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Patient Group
Patient with Covid 19 Pneumonia
|
Observational study, not applicable
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analog Scale (VAS)
時間枠:up to 12th week
|
Change from baseline visual analog scale (VAS) myalgia, arthralgia, cervical, thorocic and lumbar pain at 4th and 12th week. Pain intensity was measured with visual analogue scale for pain (0-10 mm; 0 means no pain, 10 means severe pain) which is used to measure musculoskeletal pain with very good reliability and validity. |
up to 12th week
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fatigue Severity Scale
時間枠:up to 12th week
|
The scale evaluates the fatigue severity of the participants in the last week.
Answers are scored on a seven point scale where 1 = strongly disagree and 7 = strongly agree.
The minimum score possible is nine and the highest is 63.
The higher the score, the more severe the fatigue is and the more it affects the person's activities.
|
up to 12th week
|
|
Hospital Anxiety And Depression Scale
時間枠:up to 12th week
|
The Hospital Anxiety and Depression Scale (HADS) is a measure designed to assess anxiety and depression symptoms in patients.
The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
A subscore of > 7 for depression and > 10 for anxiety would indicate a clinical case.
|
up to 12th week
|
|
Short form 12 (SF-12)
時間枠:up to 12th week
|
The SF-12 is an easy-to-administer questionnaire with proven reliability and validity, obtained by shortening and simplifying the SF-36.
It is used in the assessment of physical and mental health, the two main components of general health.
SF-12 surveys eight domains of health, such as physical functionality, physical role limitations, pain, general health, vitality, social functionality, emotional role limitations, and mental health.
Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning
|
up to 12th week
|
協力者と研究者
捜査官
- 主任研究者:Sevda MD ADAR、Afyonkarahisar Health Sciences University
- 主任研究者:Ali İzzet MD AKÇİN、Afyonkarahisar Health Sciences University
出版物と役立つリンク
一般刊行物
- Cipollaro L, Giordano L, Padulo J, Oliva F, Maffulli N. Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients. J Orthop Surg Res. 2020 May 18;15(1):178. doi: 10.1186/s13018-020-01702-w.
- Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, Doucet L, Berkani S, Oliosi E, Mallart E, Corre F, Zarrouk V, Moyer JD, Galy A, Honsel V, Fantin B, Nguyen Y. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020 Dec;81(6):e4-e6. doi: 10.1016/j.jinf.2020.08.029. Epub 2020 Aug 25.
- Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O'Connor RJ, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021 Feb;93(2):1013-1022. doi: 10.1002/jmv.26368. Epub 2020 Aug 17.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- SAA21Covid19
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。